Laboratorio Farmaceutico Erfo S.p.A (ERFO) Fair Value & Analysis
Consumer Defensive · IT · Market cap €9.4M
Fair value as of: Jul 15, 2026
From 16 valuation models · updated 27 days ago
Fair value updated Jul 15, 2026, revised from €1.31 to €0.9400 (−28.2%) since Jun 24, 2026. Share price −6.7% over the past month.
A solid business, but screening 16% overvalued on our models.
What matters now
- Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
- Our model range runs from €0.7100 (bear) to €1.18 (bull), base €0.9400. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 66/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.
How to read this chart
49‑month range €0.8541 – €3.04 · fair‑value band €0.7100 – €1.18 · the €1.12 price screens above the €0.9400 fair value. Dashed = 300-day average. As of Jul 15, 2026.
Analysis
Laboratorio Farmaceutico Erfo S.p.A (ERFO) currently trades at €1.12, while our model-based Fair Value estimate is €0.9400, implying the stock looks roughly 15.7% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Laboratorio Farmaceutico Erfo S.p.A generated revenue of €9.7M at a net margin of 7.6%. Revenue grew 64.7% year over year. It earns a return on equity of 9.3%. The stock trades on a trailing P/E of 27.5. Fundamentals as of Jul 15, 2026
Our scenario range runs from €0.7100 (bear case) to €1.18 (bull case); at €1.12, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -3% fair-value upside, at -16%, ERFO screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Growth Earnings (€1.31) versus Asset-Based (€0.6300). Highest evidence: Residual Income (76).
Notify me when ERFO reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 26
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Laboratorio Farmaceutico Erfo S.p.A. engages in the developing and production of food supplements in Italy. It provides therapeutic solutions for andrology, gastroenterology, gynecology, neurology, dentistry, orthopedics, and vascular therapeutic areas. Laboratorio Farmaceutico Erfo S.p.A. was founded in 2013 and is based in Villafranca Tirrena, Italy.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Laboratorio Farmaceutico Erfo S.p.A reported revenue of €9.7M in FY2025 versus €4.8M in FY2021, a compound +19.0%/yr. Reported net income was €382K in FY2025, compounding −24.4%/yr from FY2021.
ERFO screens 16% overvalued. Compare with Nestlé India Limited →
Peer Group
Packaged Foods · 649 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Packaged Foods median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Nestlé India Limited NESTLEIND | ₹1,427 | ₹362.37 | -75% |
| Britannia Industries Limited BRITANNIA | ₹5,413 | ₹1,870 | -65% |
| Tata Consumer Products Limited TATACONSUM | ₹1,089 | ₹327.27 | -70% |
| PT Indofood CBP Sukses Makmur Tbk ICBP | 6,650 IDR | 15,757 IDR | +137% |
| Samyang Foods Co 003230 | 1,139,000 KRW | 1,010,543 KRW | -11% |
| Patanjali Foods Limited PATANJALI | ₹413.80 | ₹157.04 | -62% |
| Vietnam Dairy Products Joint Stock Company VNM | 58,500 VND | 68,259 VND | +17% |
| PT Mayora Indah Tbk, MYOR | 1,750 IDR | 2,699 IDR | +54% |
| PT Cisarua Mountain Dairy Tbk CMRY | 4,490 IDR | 4,355 IDR | -3% |
| Nongshim Co 004370 | 348,500 KRW | 530,619 KRW | +52% |
Compare Laboratorio Farmaceutico Erfo S.p.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Laboratorio Farmaceutico Erfo S.p.A (ERFO) overvalued or undervalued?
What is the fair value of ERFO?
What is the quality score of ERFO?
What is the revenue of Laboratorio Farmaceutico Erfo S.p.A (ERFO)?
What is the net profit margin of ERFO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Laboratorio Farmaceutico Erfo S.p.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.